Opin vísindi

Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13 : The pneumococcal serotype replacement and distribution estimation (PSERENADE) project

Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13 : The pneumococcal serotype replacement and distribution estimation (PSERENADE) project


Title: Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13 : The pneumococcal serotype replacement and distribution estimation (PSERENADE) project
Author: PSERENADE Team
Date: 2021-04-02
Language: English
Scope:
University/Institute: Landspitali - The National University Hospital of Iceland
Department: Faculty of Medicine
Clinical Laboratory Services, Diagnostics and Blood Bank
Series: Microorganisms; 9(4)
ISSN: 2076-2607
DOI: https://doi.org/10.3390/microorganisms9040742
Subject: Heilahimnubólga; Pneumókokkar; Eftirlit; Global; Invasive pneumococcal disease; Pneumococcal conjugate vaccines; Pneumococcal meningitis; Surveillance; Microbiology; Microbiology (medical); Virology
URI: https://hdl.handle.net/20.500.11815/3203

Show full item record

Citation:

PSERENADE Team 2021 , ' Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13 : The pneumococcal serotype replacement and distribution estimation (PSERENADE) project ' , Microorganisms , vol. 9 , no. 4 , 742 . https://doi.org/10.3390/microorganisms9040742

Abstract:

Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.

Description:

Funding text The PSERENADE project is funded by the Bill and Melinda Gates Foundation as part of the World Health Organization Pneumococcal Vaccines Technical Coordination Project, grant number INV-010429/OPP1189065. Publisher Copyright: © 2021 by the authors.

Files in this item

This item appears in the following Collection(s)